Evaluation of Clinical Signs and Symptoms of Chronic Heart Failure in Patients Treated With Candesartan Cilexetil in Croatia
1 other identifier
observational
500
1 country
15
Brief Summary
The purpose of this study is to determine whether treatment with candesartan cilexetil for at least 6 months in patients with chronic heart failure improves clinical signs and symptoms of chronic heart failure.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2009
Shorter than P25 for all trials
15 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2009
CompletedFirst Submitted
Initial submission to the registry
September 24, 2009
CompletedFirst Posted
Study publicly available on registry
September 25, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2010
CompletedJanuary 7, 2011
January 1, 2011
5 months
September 24, 2009
January 6, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To evaluate clinical signs and symptoms of chronic heart failure (in terms of NYHA status, fluid retention and tiredness/fatigue) after at least 6 months of treatment with candesartan cilexetil
1 visit (after at least 6 months of treatment)
Secondary Outcomes (3)
To evaluate ventricular function after at least 6 months of treatment with candesartan cilexetil
1 visit (after at least 6 months of treatment)
To gain insight into usage of candesartan cilexetil in real life for chronic heart failure in Croatia
1 visit (after at least 6 months of treatment)
To evaluate patient's compliance with prescribed treatment
1 visit (after at least 6 months of treatment)
Study Arms (1)
1
Cardiologist´s office patients
Eligibility Criteria
Primary Care
You may qualify if:
- Patients with diagnosed chronic heart failure
- Patients treated for at least 6 months with candesartan cilexetil
- Signed Informed consent
You may not qualify if:
- Hypersensitivity to candesartan cilexetil
- Pregnancy / lactation
- Severe hepatic impairment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (15)
Research Site
Biograd na Moru, Croatia
Research Site
Bjelovar, Croatia
Reserach Site
Čakovec, Croatia
Research Site
Karlovac, Croatia
Reserach Site
Krapinske Toplice, Croatia
Research Site
Novi Marof, Croatia
Research Site
Opatija, Croatia
Research Site
Osijek, Croatia
Research Site
Pula, Croatia
Research Site
Rijeka, Croatia
Reserach Site
Sl. Brod, Croatia
Research Site
Split, Croatia
Research Site
Stubičke Toplice, Croatia
Reserach Site
Zabok, Croatia
Research Site
Zagreb, Croatia
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
September 24, 2009
First Posted
September 25, 2009
Study Start
September 1, 2009
Primary Completion
February 1, 2010
Study Completion
February 1, 2010
Last Updated
January 7, 2011
Record last verified: 2011-01